Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND; FSE: CWY0), a Vancouver-based clinical-stage biotech firm, has announced the filing of a patent application in Hong Kong for a new combination therapy aimed at treating major depressive disorder (MDD). This innovative treatment merges Clearmind's proprietary compound, 5-methoxy-2-aminoindane (MEAI), with Palmitoylethanolamide (PEA), obtained through its collaboration with NeuroThera Labs Inc. The combination represents a non-hallucinogenic neuroplastogen option, distinguishing itself from traditional antidepressants like SSRIs.
MDD affects more than 332 million individuals worldwide, and the market for depression therapies is projected to surpass $25 billion by 2030. Clearmind’s MEAI-PEA therapy could provide a safer, more accessible alternative compared to existing treatments, addressing a significant need in a growing market focused on mental health solutions.
Clearmind is dedicated to developing innovative psychoactive-derived therapeutics to tackle prevalent and underserved health issues, including alcohol use disorder. The company boasts a robust intellectual property portfolio, encompassing nineteen patent families and 31 granted patents. With a proactive approach, Clearmind aims to expand its intellectual property through additional patents, emphasizing its commitment to research and commercialization of psychedelic-based compounds.
Investors and stakeholders can find further details on Clearmind's endeavors and latest updates on their official website. The company also notes that this announcement contains forward-looking statements, reflecting expectations and potential future developments, which carry inherent uncertainties and risks.
Overall, Clearmind’s recent patent filing signifies a promising advancement in depression therapy, illustrating the evolving landscape of mental health treatment and the potential for novel, non-hallucinogenic options in a rapidly expanding market.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) recently made headlines with its filing of a patent application for an innovative combination therapy aimed at treating major depressive disorder (MDD). This approach combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA). Given that depression affects over 332 million individuals worldwide, and the market for depression therapies is projected to exceed $25 billion by 2030, Clearmind is strategically positioning itself in a rapidly growing segment.
The non-hallucinogenic nature of Clearmind's therapy may appeal to patients seeking alternatives to traditional antidepressants, which frequently come with significant side effects. This positions Clearmind as a potential disruptor in the sector, especially as patients and healthcare providers increasingly prioritize safety and accessibility in mental health treatments. The collaboration with NeuroThera Labs strengthens Clearmind's capabilities, providing a pathway to enhanced research and development of neuroplastogen-derived therapeutics.
Investors should closely monitor Clearmind's progress, particularly regarding their patent strategy and the subsequent clinical trials that will be required to validate the efficacy and safety of the MEAI-PEA combination. While the patent filing is a positive step and suggests a robust intellectual property portfolio, it is crucial to recognize that patent approvals are not guaranteed, and market acceptance hinges on clinical outcomes.
Given the therapeutic promise and potential market size, Clearmind represents an intriguing opportunity for investors in the biotech space. However, with high-reward opportunities come inherent risks, including regulatory hurdles and competition from established pharmaceutical companies. It’s advisable for investors to conduct thorough due diligence and consider diversifying their portfolios to mitigate potential volatility associated with such high-risk biotech investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030
Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).
This innovative treatment blends Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced via its partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).
The patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how the patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression and how the Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
How does the partnership with SciSparc Ltd. (SPRC) enhance Clearmind’s ability to develop its MEAI-PEA combination therapy for major depressive disorder?
What specific advantages does the MEAI-PEA synergy offer over traditional antidepressants in treating major depressive disorder, considering the company’s collaboration with SciSparc Ltd. (SPRC)?
Can you elaborate on the potential market implications for Clearmind’s MEAI-PEA therapy in the context of the $25 billion depression treatment market and the involvement of SciSparc Ltd. (SPRC)?
How does Clearmind plan to leverage its intellectual property strategy, including its partnership with SciSparc Ltd. (SPRC), to successfully commercialize the MEAI-PEA therapy?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
